CagriSema vs tirzepatide: is the Novo combo actually better?
On the 2024 REDEFINE-1 readout: no, not meaningfully better. CagriSema produced 22.7% mean weight loss at 68 weeks, similar to tirzepatide's SURMOUNT-1 (22.5% at 72 weeks). The pre-trial market expected >25%; the actual number triggered Novo's stock drop and a re-think on Novo's competitive position. Different mechanism (amylin + GLP-1 vs GLP-1 + GIP) but similar real-world outcomes.
Last reviewed · Panya.health editorial
What CagriSema actually is
CagriSema combines cagrilintide (a long-acting amylin / calcitonin receptor agonist) with semaglutide. The two are co-formulated for once-weekly subcutaneous injection. Mechanism stack: GLP-1 receptor agonism (semaglutide) handles the satiety + insulin signaling; amylin receptor agonism (cagrilintide) handles gastric-emptying delay via a different brainstem pathway, with the central rationale that the two pathways are complementary rather than redundant. Novo's REDEFINE Phase 3 program tests CagriSema in obesity and T2D. The compound is not approved as of April 2026; readouts continue.
What the REDEFINE-1 readout actually showed
Novo announced REDEFINE-1 results in December 2024: CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, weekly) produced 22.7% mean weight loss at 68 weeks vs placebo. For comparison: semaglutide alone was 16.1%, cagrilintide alone was 11.8%, placebo was 2.3%. The pre-trial market consensus was >25% for the combo, based partly on Novo's earlier Phase 1 / 2 signal and partly on the simple additivity assumption (16.1% + 11.8% / 2 ≈ 14% on naive averaging, but biology-of-combinations reasoning suggested closer to 26% via signal-pathway non-redundancy). The 22.7% number was real but disappointing in context. Novo's stock dropped roughly 20% on the readout.
How that compares to tirzepatide today
SURMOUNT-1 tirzepatide at 15 mg / 72 weeks delivered 22.5% mean weight loss vs placebo. SURMOUNT-3 with intensive lifestyle prep delivered 26.6%. CagriSema at REDEFINE-1's 68-week endpoint sits inside the same range as tirzepatide's standard-care arm. There's no clean head-to-head trial yet, but the indirect comparison is roughly: equivalent on the primary weight-loss endpoint, different on side-effect profile (CagriSema has somewhat-different GI tolerability pattern, slightly less acute nausea but more prolonged early satiety per the trial reports). For someone tolerating tirzepatide well, switching to CagriSema is an opaque coin-flip; for someone who can't tolerate tirzepatide's GI signature, CagriSema might be worth trying when approved.
Where Panya stands
Cagrilintide is documented at panya.health/peptide/cagrilintide; tirzepatide regional pricing pages live at panya.health/compound/tirzepatide. Panya routes to licensed clinicians for tirzepatide today. CagriSema is not yet approved; Panya does NOT route to research-chem cagrilintide because the molecule is harder to source reliably than tirzepatide and the safety case for waiting for approval is real. Honest read on the choice: there's no compelling reason to chase CagriSema specifically over working tirzepatide based on the REDEFINE-1 numbers. If approval comes through 2026-2027 and head-to-head comparator trials run, that calculus may shift; for now, the Lilly portfolio (tirzepatide present, retatrutide future) looks slightly ahead.
Read about this peptide
Related posts
Tirzepatide monthly cost across 10 markets: US brand, US compounded, UK private, Scandinavia, Germany, Thailand clinic, Thailand direct, Japan, Singapore, Australia. The real numbers, updated April 20...
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.